FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999839461> ?p ?o ?g. }

• W1999839461 endingPage "231" @default.
• W1999839461 startingPage "223" @default.
• W1999839461 abstract "Background There is no generally accepted treatment for chronic hepatitis B (HB) infection in children. Objectives To evaluate the efficacy of a prolonged course of high dose interferon alone or after prednisone priming in children with chronic HB infection. Methods The outcome of 31 children with HB e antigen (HBeAg)-positive chronic hepatitis who randomly received either no treatment (n = 9) or 10 million units of interferon alpha-2b/m2, alone (n = 13) or after prednisone priming (n = 9), three times weekly for 1 year was studied. Results One patient withdrew from treatment. By the end of the first year treatment induced a loss of HB virus DNA and HBeAg from serum in 10 of 21 patients (48%), and a loss of HB surface antigen (HBsAg) in 4 (19%). Alanine aminotransferase values became normal in one patient (4.8%). Response rates in the two groups of treated patients were similar. In controls only one patient lost HBeAg and HBV DNA (11%; P = 0.05), and none lost HBsAg or showed alanine aminotransferase normalization (P = 0.21 and 0.70, respectively). After a posttreatment 2-year follow-up there were still no differences in the response rates of the two treatments; of the 21 pooled treated patients, 61% lost HBeAg and DNA and 67% normalized alanine aminotransferase (vs. 33 and 44% of controls, respectively; P = 0.32 and 0.40). Reversion to HBeAg and HBV DNA negativity in treated patients occurred significantly earlier (P = 0.02 and 0.006, respectively) than in controls. No further patient lost HBsAg, but one reacquired HBsAg. Treated patients had posttreatment histologic scores better than controls (P = 0.03). Conclusions Our medium term follow-up results indicate that a prolonged course of high dose interferon in children with chronic HB infection, regardless of prednisone priming, poorly affects response rates but significantly speeds termination of active viral replication." @default.
• W1999839461 created "2016-06-24" @default.
• W1999839461 creator A5010842275 @default.
• W1999839461 creator A5011653292 @default.
• W1999839461 creator A5018028303 @default.
• W1999839461 creator A5020661506 @default.
• W1999839461 creator A5021592888 @default.
• W1999839461 creator A5023044832 @default.
• W1999839461 creator A5023138201 @default.
• W1999839461 creator A5068575794 @default.
• W1999839461 creator A5076854299 @default.
• W1999839461 date "1996-03-01" @default.
• W1999839461 modified "2023-09-27" @default.
• W1999839461 title "Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection" @default.
• W1999839461 cites W1957878455 @default.
• W1999839461 cites W1969872269 @default.
• W1999839461 cites W1974363762 @default.
• W1999839461 cites W1976495172 @default.
• W1999839461 cites W1982562618 @default.
• W1999839461 cites W1991892150 @default.
• W1999839461 cites W2013748326 @default.
• W1999839461 cites W2022794533 @default.
• W1999839461 cites W2028094679 @default.
• W1999839461 cites W2040175589 @default.
• W1999839461 cites W2055270948 @default.
• W1999839461 cites W2055293911 @default.
• W1999839461 cites W2060958314 @default.
• W1999839461 cites W2061614087 @default.
• W1999839461 cites W2068146271 @default.
• W1999839461 cites W2073559033 @default.
• W1999839461 cites W2081492545 @default.
• W1999839461 cites W2092305485 @default.
• W1999839461 cites W2115956200 @default.
• W1999839461 cites W2120332259 @default.
• W1999839461 cites W2124803194 @default.
• W1999839461 cites W2159762677 @default.
• W1999839461 cites W2160453530 @default.
• W1999839461 cites W2164523298 @default.
• W1999839461 cites W2331252455 @default.
• W1999839461 cites W2333884882 @default.
• W1999839461 cites W2341203768 @default.
• W1999839461 cites W2402295136 @default.
• W1999839461 cites W4301647592 @default.
• W1999839461 cites W64327748 @default.
• W1999839461 doi "https://doi.org/10.1097/00006454-199603000-00010" @default.
• W1999839461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8852910" @default.
• W1999839461 hasPublicationYear "1996" @default.
• W1999839461 type Work @default.
• W1999839461 sameAs 1999839461 @default.
• W1999839461 citedByCount "47" @default.
• W1999839461 countsByYear W19998394612012 @default.
• W1999839461 countsByYear W19998394612013 @default.
• W1999839461 countsByYear W19998394612014 @default.
• W1999839461 countsByYear W19998394612015 @default.
• W1999839461 countsByYear W19998394612017 @default.
• W1999839461 countsByYear W19998394612018 @default.
• W1999839461 countsByYear W19998394612019 @default.
• W1999839461 countsByYear W19998394612021 @default.
• W1999839461 countsByYear W19998394612023 @default.
• W1999839461 crossrefType "journal-article" @default.
• W1999839461 hasAuthorship W1999839461A5010842275 @default.
• W1999839461 hasAuthorship W1999839461A5011653292 @default.
• W1999839461 hasAuthorship W1999839461A5018028303 @default.
• W1999839461 hasAuthorship W1999839461A5020661506 @default.
• W1999839461 hasAuthorship W1999839461A5021592888 @default.
• W1999839461 hasAuthorship W1999839461A5023044832 @default.
• W1999839461 hasAuthorship W1999839461A5023138201 @default.
• W1999839461 hasAuthorship W1999839461A5068575794 @default.
• W1999839461 hasAuthorship W1999839461A5076854299 @default.
• W1999839461 hasConcept C126322002 @default.
• W1999839461 hasConcept C203014093 @default.
• W1999839461 hasConcept C2522874641 @default.
• W1999839461 hasConcept C2775940106 @default.
• W1999839461 hasConcept C2776178377 @default.
• W1999839461 hasConcept C2777410769 @default.
• W1999839461 hasConcept C2778720950 @default.
• W1999839461 hasConcept C2780593183 @default.
• W1999839461 hasConcept C2781228144 @default.
• W1999839461 hasConcept C2909179924 @default.
• W1999839461 hasConcept C71924100 @default.
• W1999839461 hasConcept C90924648 @default.
• W1999839461 hasConceptScore W1999839461C126322002 @default.
• W1999839461 hasConceptScore W1999839461C203014093 @default.
• W1999839461 hasConceptScore W1999839461C2522874641 @default.
• W1999839461 hasConceptScore W1999839461C2775940106 @default.
• W1999839461 hasConceptScore W1999839461C2776178377 @default.
• W1999839461 hasConceptScore W1999839461C2777410769 @default.
• W1999839461 hasConceptScore W1999839461C2778720950 @default.
• W1999839461 hasConceptScore W1999839461C2780593183 @default.
• W1999839461 hasConceptScore W1999839461C2781228144 @default.
• W1999839461 hasConceptScore W1999839461C2909179924 @default.
• W1999839461 hasConceptScore W1999839461C71924100 @default.
• W1999839461 hasConceptScore W1999839461C90924648 @default.
• W1999839461 hasIssue "3" @default.
• W1999839461 hasLocation W19998394611 @default.
• W1999839461 hasLocation W19998394612 @default.
• W1999839461 hasOpenAccess W1999839461 @default.
• W1999839461 hasPrimaryLocation W19998394611 @default.

• next